Kestra Private Wealth Services LLC Boosts Stake in Edwards Lifesciences Co. (NYSE:EW)

Kestra Private Wealth Services LLC increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 9.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,796 shares of the medical research company’s stock after buying an additional 396 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Edwards Lifesciences were worth $366,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in EW. AustralianSuper Pty Ltd purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $168,519,000. Nordea Investment Management AB increased its holdings in Edwards Lifesciences by 1,224.1% in the fourth quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock valued at $123,261,000 after buying an additional 1,488,791 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock valued at $1,138,575,000 after acquiring an additional 1,390,427 shares during the period. FMR LLC boosted its stake in shares of Edwards Lifesciences by 61.1% during the 3rd quarter. FMR LLC now owns 3,111,385 shares of the medical research company’s stock worth $215,557,000 after acquiring an additional 1,179,637 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the 3rd quarter valued at approximately $60,971,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. Citigroup upped their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a report on Wednesday, April 3rd. Piper Sandler raised their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a “neutral” rating in a report on Friday, April 26th. Evercore ISI cut their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating for the company in a research report on Friday, April 26th. Mizuho increased their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $93.27.

Insider Buying and Selling

In other news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $14,639,824.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Bernard J. Zovighian purchased 580 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, May 6th. The stock was purchased at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares in the company, valued at $14,639,824.29. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 237,749 shares of company stock valued at $20,920,934. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Trading Up 0.9 %

NYSE EW opened at $85.85 on Wednesday. The firm’s 50 day moving average price is $90.05 and its two-hundred day moving average price is $79.69. The stock has a market cap of $51.73 billion, a price-to-earnings ratio of 37.00, a PEG ratio of 3.59 and a beta of 1.10. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.